CD151基因对血管内皮细胞表面整合素α3β1／α6β1表达的影响

目的研究重组腺相关病毒介导的CD151基因转染人脐静脉内皮细胞（HUVECs）对整合素α3β1／α6β1表达的影响。方法包装携带CD151、CD151-QRD和CD151-ARSA的重组腺相关病毒，转染HUVECs细胞，用Western Blot和流式细胞仪检测HUVECs细胞CD151及整合素a3131／a6131的表达。结果CD-51组及其各突变体组的CD151表达均明显高于对照组（P〈0．01），但3组间互相比较CD151蛋白表达差异无统计学意义（P〉0．05）。Western Blot及流式细胞仪检测显示CDl51组α3、α6及β1的表达明显高于对照组、CD151-QRD组和CD151-ARSA组（P〈0．05），其余各组间比较差异无统计学意义（P〉0．05）。结论CD151基因转染能促进整合素α3β1／α6β1的蛋白表达，其机制可能与CD151胞外大环QRD194-196。“及C末端囊泡运输基序YRSL”。。。有关。

Role of conventional therapies in the era of biological treatment in Crohn’s disease

Outstanding progress regarding the pathophysiology of Crohn's disease (CD) has led to the development of innovative therapeutic concepts. Numerous controlled trials have been performed in CD. This review concentrates on the results of randomized,placebo-controlled trials,and meta-analyses when available,that provide the highest degree of evidence. Current guidelines on the management of CD recommend a step-up approach to treatment involving the addition of more powerful therapies as the severity of disease and refractoriness to therapy increase. The advent of biological drugs has opened new therapeutic horizons for treating CD,modifying the treatment goals. However,the large majority of patients with CD will be managed through conventional therapy,even if they are a prelude to biological therapy.